<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721158</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00255470-2</org_study_id>
    <nct_id>NCT04721158</nct_id>
  </id_info>
  <brief_title>CGM Use in Children With Type 2 Diabetes</brief_title>
  <acronym>IMPaCT2</acronym>
  <official_title>IMPlementation of Continuous Glucose Monitoring in Children With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective study is to determine if trial use of a Dexcom G6 CGM system&#xD;
      for a 10 day wear period in pediatric Type 2 diabetes patients improves short term time in&#xD;
      range glucose control and 3-6 month glycemic control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Time in range glucose control</measure>
    <time_frame>Baseline and 10 days</time_frame>
    <description>Change in time in range glucose control from baseline to 10 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hemoglobin A1c</measure>
    <time_frame>Baseline, 3 months and 6 months</time_frame>
    <description>Changes in HbA1c from baseline to follow-up.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Hyperglycemia Due to Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CGM Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Children with type 2 diabetes will wear a continuous glucose monitor for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous glucose monitor</intervention_name>
    <description>Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.</description>
    <arm_group_label>CGM Arm</arm_group_label>
    <other_name>Dexcom G6 CGM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes, diabetes duration &gt;3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior use of CGM&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Risa M Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Risa M Wolf, MD</last_name>
    <phone>410955-6463</phone>
    <email>rwolf@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheela N Magge, MD, MSCE</last_name>
    <phone>410-955-6463</phone>
    <email>smagge3@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Pediatric Diabetes Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Risa M Wolf, MD</last_name>
      <phone>410-955-6463</phone>
      <email>rwolf@jhu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>continuous glucose monitoring (CGM)</keyword>
  <keyword>Hemoglobin A1c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

